Jason Ehrlich, MD, PhD is the Global Head of Clinical Ophthalmology and a Senior Group Medical Director within Genentech’s Product Development organization. In this role, he leads a team of dedicated professionals, all of whom share a passion for addressing the leading causes of blindness and vision impairment through the thoughtful and effective development of new therapeutics. He oversees all late-stage ophthalmology clinical development at Genentech and Roche; this portfolio includes Lucentis, Ranibizumab Port Delivery System (currently in Phase II), and lampalizumab (currently in Phase III). Jason first joined Genentech as a clinical research fellow in 2008, and has been in positions of increasing responsibility within Ophthalmology Clinical Development since then. He completed ophthalmology residency, as well as his MD and PhD degrees, at Stanford.